Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Follicular Lymphoma

Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_3891-1


Follicular lymphoma (FL), in its usual form (UFL), is a malignant neoplasm composed of germinal center (GC) B cells, namely, centroblasts and centrocytes, which are presumed to originate from the GC light zone and usually display an at least partially follicular growth pattern (Swerdlow et al. 2016a). Particular FL variants include the pediatric-type FL, occurring mainly in children but also rarely in young adults, the duodenal–type FL, and a particular condition named in situ follicular neoplasia, which is considered as a precursor lesion with low rate of progression.

The definition of FL requires the lack of diffuse areas composed of large blastic cells, which should lead to the diagnosis of diffuse large cell lymphoma (DLCL), the most common type of FL transformation. Primary cutaneous lymphomas of follicular origin are not considered as bona fide FL variants and deserve a separate classification.

Clinical Features

Incidence, Age, and Sex

FL has its highest incidence in...

This is a preview of subscription content, log in to check access.

References and Further Reading

  1. Huet, S., Szafer-Glusman, E., Tesson, B., Xerri, L., Fairbrother, W. J., Mukhyala, K., Bolen, C., Punnoose, E., Tonon, L., Chassagne-Clément, C., Feugier, P., Viari, A., Jardin, F., Salles, G., & Sujobert, P. (2017a). BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab. American Journal of Hematology, 92, 515–519.CrossRefGoogle Scholar
  2. Huet, S., Xerri, L., Tesson, B., Mareschal, S., Taix, S., Mescam-Mancini, L., Sohier, E., Carrère, M., Lazarovici, J., Casasnovas, O., Tonon, L., Boyault, S., Hayette, S., Haioun, C., Fabiani, B., Viari, A., Jardin, F., & Salles, G. (2017b). EZH2 alterations in follicular lymphoma: Biological and clinical correlations. Blood Cancer Journal, 7, e555.CrossRefGoogle Scholar
  3. Jurinovic, V., Kridel, R., Staiger, A. M., Szczepanowski, M., Horn, H., Dreyling, M. H., Rosenwald, A., Ott, G., Klapper, W., Zelenetz, A. D., Barr, P. M., Friedberg, J. W., Ansell, S., Sehn, L. H., Connors, J. M., Gascoyne, R. D., Hiddemann, W.,Unterhalt, M., Weinstock, D. M., & Weigert, O. (2016). Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood, 128, 1112–1120.CrossRefGoogle Scholar
  4. Kahl, B. S., & Yang, D. T. (2016). Follicular lymphoma: Evolving therapeutic strategies. Blood, 127, 2055–2063.CrossRefGoogle Scholar
  5. Koch, K., Hoster, E., Ziepert, M., Unterhalt, M., Ott, G., Rosenwald, A., Hansmann, M. L., Bernd, W., Stein, H., Pöschel, V., Dreyling, M., Trümper, L., Löffler, M., Schmitz, N., Hiddemann, W., Pfreundschuh, M., & Klapper, W. (2016). Clinical, pathological and genetic features of follicular lymphoma grade 3A: A joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL. Annals of Oncology, 27, 1323–1329.CrossRefGoogle Scholar
  6. Kridel, R., Chan, F. C., Mottok, A., Boyle, M., Farinha, P., Tan, K., Meissner, B., Bashashati, A., McPherson, A., Roth, A., Shumansky, K., Yap, D., Ben-Neriah, S., Rosner, J., Smith, M. A., Nielsen, C., Giné, E., Telenius, A., Ennishi, D., Mungall, A., Moore, R., Morin, R. D., Johnson, N. A., Sehn, L. H., Tousseyn, T., Dogan, A., Connors, J. M., Scott, D. W., Steidl, C., Marra, M. A., Gascoyne, R. D., & Shah, S. P. (2016). Histological transformation and progression in follicular lymphoma: A clonal evolution study. PLoS Medicine, 13, e1002197.CrossRefGoogle Scholar
  7. Laurent, C., Baron, M., Amara, N., Haioun, C., Dandoit, M., Maynadié, M., Parrens, M., Vergier, B., Copie-Bergman, C., Fabiani, B., Traverse-Glehen, A., Brousse, N., Copin, M. C., Tas, P., Petrella, T., Rousselet, M. C., Brière, J., Charlotte, F., Chassagne-Clement, C., Rousset, T., Xerri, L., Moreau, A., Martin, A., Damotte, D., Dartigues, P., Soubeyran, I., Peoch, M., Dechelotte, P., Michiels, J. F., de Mascarel, A., Berger, F., Bossard, C., Arbion, F., Quintin-Roué, I., Picquenot, J. M., Patey, M., Fabre, B., Sevestre, H., Le Naoures, C., Chenard-Neu, M. P., Bastien, C., Thiebault, S., Martin, L., Delage, M., Filleron, T., Salles, G., Molina, T. J., Delsol, G., Brousset, P., & Gaulard, P. (2017). Impact of expert pathologic review of lymphoma diagnosis: Study of patients from the French Lymphopath Network. Journal of Clinical Oncology, 35, 2008–2017.CrossRefGoogle Scholar
  8. Le, K. S., Thibult, M. L., Just-Landi, S., Pastor, S., Gondois-Rey, F., Granjeaud, S., Broussais, F., Bouabdallah, R., Colisson, R., Caux, C., Ménétrier-Caux, C., Leroux, D., Xerri, L., & Olive, D. (2016). Follicular B lymphomas generate regulatory T cells via the ICOS/ICOSL pathway and are susceptible to treatment by anti-ICOS/ICOSL therapy. Cancer Research, 76, 4648–4660.CrossRefGoogle Scholar
  9. Leich, E., Hoster, E., Wartenberg, M., Unterhalt, M., Siebert, R., Koch, K., Klapper, W., Engelhard, M., Puppe, B., Horn, H., Staiger, A. M., Stuhlmann-Laeisz, C., Bernd, H. W., Feller, A. C., Hummel, M., Lenze, D., Stein, H., Hartmann, S., Hansmann, M. L., Möller, P., Hiddemann, W., Dreyling, M., Ott, G., Rosenwald, A., & German Low Grade Lymphoma Study Group (GLSG). (2016). Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus. Leukemia, 30, 854–860.CrossRefGoogle Scholar
  10. Louissaint, A., Jr., Schafernak, K. T., Geyer, J. T., Kovach, A. E., Ghandi, M., Gratzinger, D., Roth, C. G., Paxton, C. N., Kim, S., Namgyal, C., Morin, R., Morgan, E. A., Neuberg, D. S., South, S. T., Harris, M. H., Hasserjian, R. P., Hochberg, E. P., Garraway, L. A., Harris, N. L., & Weinstock, D. M. (2016). Pediatric-type nodal follicular lymphoma: A biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 128, 1093–1100.CrossRefGoogle Scholar
  11. Mackrides, N., Campuzano-Zuluaga, G., Maque-Acosta, Y., Moul, A., Hijazi, N., Ikpatt, F. O., Levy, R., Verdun, R. E., Kunkalla, K., Natkunam, Y., Lossos, I. S., Vega, F., & Chapman, J. (2017). Epstein-Barr virus-positive follicular lymphoma. Modern Pathology, 30, 519–529.CrossRefGoogle Scholar
  12. Miao, Y., Hu, S., Lu, X., Li, S., Wang, W., Medeiros, L. J., & Lin, P. (2016). Double-hit follicular lymphoma with MYC and BCL2 translocations: A study of 7 cases with a review of literature. Human Pathology, 58, 72–77.CrossRefGoogle Scholar
  13. Quintanilla-Martinez, L., Sander, B., Chan, J. K., Xerri, L., Ott, G., Campo, E., & Swerdlow, S. H. (2016). Indolent lymphomas in the pediatric population: Follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Archiv, 468, 141–157.CrossRefGoogle Scholar
  14. Sarkozy, C., Trneny, M., Xerri, L., Wickham, N., Feugier, P., Leppa, S., Brice, P., Soubeyran, P., Gomes Da Silva, M., Mounier, C., Offner, F., Dupuis, J., Caballero, D., Canioni, D., Paula, M., Delarue, R., Zachee, P., Seymour, J., Salles, G., & Tilly, H. (2016). Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line Immunochemotherapy in the PRIMA trial. Journal of Clinical Oncology, 34, 2575–2582.CrossRefGoogle Scholar
  15. Schmidt, J., Ramis-Zaldivar, J. E., Nadeu, F., Gonzalez-Farre, B., Navarro, A., Egan, C., Montes-Mojarro, I. A., Marafioti, T., Cabeçadas, J., van der Walt, J., Dojcinov, S., Rosenwald, A., Ott, G., Bonzheim, I., Fend, F., Campo, E., Jaffe, E. S., Salaverria, I., & Quintanilla-Martinez, L. (2017). Mutations of MAP 2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 130, 323–327.CrossRefGoogle Scholar
  16. Siddiqi, I. N., Friedman, J., Barry-Holson, K. Q., Ma, C., Thodima, V., Kang, I., Padmanabhan, R., Dias, L. M., Kelly, K. R., Brynes, R. K., Kamalakaran, S., & Houldsworth, J. (2016). Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations. Modern Pathology, 29, 570–581.CrossRefGoogle Scholar
  17. Swerdlow, S., Campo, E., Harris, N. E., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J., & Vardiman, J. W. (2016a). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press.Google Scholar
  18. Swerdlow, S. H., Kuzu, I., Dogan, A., Dirnhofer, S., Chan, J. K., Sander, B., Ott, G., Xerri, L., Quintanilla-Martinez, L., & Campo, E. (2016b). The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Archiv, 468, 259–275.CrossRefGoogle Scholar
  19. Xerri, L., Dirnhofer, S., Quintanilla-Martinez, L., Sander, B., Chan, J. K., Campo, E., Swerdlow, S. H., & Ott, G. (2016). The heterogeneity of follicular lymphomas: From early development to transformation. Virchows Archiv, 468, 127–139.CrossRefGoogle Scholar
  20. Xerri, L., Huet, S., Venstrom, J. M., Szafer-Glusman, E., Fabiani, B., Canioni, D., Chassagne-Clément, C., Dartigues-Cuilléres, P., Charlotte, F., Laurent, C., Gelas-Dore, B., Bolen, C. R., Punnoose, E., Bouabdallah, R., Brice, P., Morschhauser, F., Cartron, G., Olive, D., Salles, G., & a LYSA study. (2017). Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. Human Pathology, 64, 128–136.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Bio-Pathology, Institut Paoli-CalmettesCRCM, INSERM, CNRS, Aix-Marseille UniversitéMarseilleFrance